Trial Profile

Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veliparib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Sponsors AbbVie; AbbVie Germany

03 Apr 2019 Results of ctDNA analysis assessing on-treatment genomic alterations, presented at the 110th Annual Meeting of the American Association for Cancer Research
22 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
11 Dec 2018 Results evaluating the efficacy and tolerability of veliparib plus FOLFIRI chemotherapy regimen in previously untreated metastatic colorectal cancer patients published in the British Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com